CL2022003507A1 - Composición y método para tratar el dolor crónico - Google Patents

Composición y método para tratar el dolor crónico

Info

Publication number
CL2022003507A1
CL2022003507A1 CL2022003507A CL2022003507A CL2022003507A1 CL 2022003507 A1 CL2022003507 A1 CL 2022003507A1 CL 2022003507 A CL2022003507 A CL 2022003507A CL 2022003507 A CL2022003507 A CL 2022003507A CL 2022003507 A1 CL2022003507 A1 CL 2022003507A1
Authority
CL
Chile
Prior art keywords
chronic pain
composition
treating chronic
relates
treating
Prior art date
Application number
CL2022003507A
Other languages
English (en)
Inventor
Richard Hopkins
Meghan Gail Thomas
Oludare Odumosu
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901947A external-priority patent/AU2020901947A0/en
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of CL2022003507A1 publication Critical patent/CL2022003507A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden ?9-tetrahidrocannabinol (THC), cannabidiol (CBD) y cannabigerol (CBG) y un componente terpénico, y su uso en el tratamiento del dolor crónico. La invención también se refiere a métodos para tratar el dolor crónico, especialmente el dolor crónico en atletas.
CL2022003507A 2020-06-12 2022-12-09 Composición y método para tratar el dolor crónico CL2022003507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2020901947A AU2020901947A0 (en) 2020-06-12 Composition and method for treating chronic pain

Publications (1)

Publication Number Publication Date
CL2022003507A1 true CL2022003507A1 (es) 2023-06-09

Family

ID=78523907

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003507A CL2022003507A1 (es) 2020-06-12 2022-12-09 Composición y método para tratar el dolor crónico

Country Status (14)

Country Link
US (1) US20230218566A1 (es)
EP (1) EP4164628A4 (es)
JP (1) JP2023529476A (es)
KR (1) KR20230069080A (es)
CN (1) CN115843248A (es)
AU (1) AU2021215262B2 (es)
BR (1) BR112022025302A2 (es)
CA (1) CA3186718A1 (es)
CL (1) CL2022003507A1 (es)
CO (1) CO2023000130A2 (es)
IL (1) IL299008A (es)
MX (1) MX2022015799A (es)
PE (1) PE20230837A1 (es)
WO (1) WO2021248207A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220387256A1 (en) * 2021-06-03 2022-12-08 Kent Byron Vial With Metered Dispenser
WO2023014818A2 (en) * 2021-08-03 2023-02-09 Pebble Global Holdings Non-psychoactive multi-cannabinoid and terpene-based therapeutic compositions and methods of their administration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102447510B1 (ko) * 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
US20200281890A1 (en) * 2017-09-25 2020-09-10 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
EP3704263A4 (en) * 2017-10-30 2021-08-25 Endocanna Health, Inc. GRAPHIC USER INTERFACES FOR DETERMINING PERSONALIZED ENDOCANNABINOID GENOTYPES AND RELATED RECOMMENDATIONS
WO2019165387A1 (en) * 2018-02-23 2019-08-29 Spirtos Nicola Michael Cannabis based therapeutic and method of use
US20230110830A1 (en) * 2018-04-09 2023-04-13 Ellevet Sciences Hemp extract for treatment of pain in animals
AU2018100928A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for opioid sparing
AU2018100924A4 (en) * 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
WO2020093170A1 (en) * 2018-11-09 2020-05-14 Cronos Group Inc. Liquid composition for an electronic vapor device
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods

Also Published As

Publication number Publication date
EP4164628A4 (en) 2024-06-19
CN115843248A (zh) 2023-03-24
KR20230069080A (ko) 2023-05-18
AU2021215262A1 (en) 2021-11-04
PE20230837A1 (es) 2023-05-19
CA3186718A1 (en) 2021-12-16
AU2021215262B2 (en) 2023-12-14
IL299008A (en) 2023-02-01
BR112022025302A2 (pt) 2023-02-28
CO2023000130A2 (es) 2023-05-19
MX2022015799A (es) 2023-04-11
WO2021248207A1 (en) 2021-12-16
JP2023529476A (ja) 2023-07-10
US20230218566A1 (en) 2023-07-13
EP4164628A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
Farid et al. Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CO2019013887A2 (es) Composiciones y tratamientos para el trastorno del sueño
BR112019001794A2 (pt) composição de cannabis
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
AR122059A1 (es) Usos y formulaciones de cannabinoides
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
BRPI0913665B8 (pt) composição para tratamento de pressão intraocular aumentada em um paciente, compreendendo extratos de vaccinum myrtillus e de casca de pinheiro
EA201891752A2 (ru) Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
BR112022022204A2 (pt) Usos e formulações de canabinoides
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
AR081024A1 (es) Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso
CO2022011987A2 (es) Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol
PE20230246A1 (es) Composicion farmaceutica en base a thc y cbd para el tratamiento del dolor cronico refractario